Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brian Jalbert

Physician Assistant Richmond, VA Physician Assistant

NPI 1790814564 CMS profile 10672701

7001 Forest Ave, Suite 301, Richmond, VA 23230

Open in the dashboard

General payments

$5,459

245 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Jalbert of Richmond, VA is reported in the CMS Open Payments database as having received $5,459 across 245 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,631 72
2024 General $1,762 76
2023 General $1,198 52
2022 General $836 43
2021 General $32 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Jalbert
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Brian Jalbert were reported at $1,631. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Brian Jalbert Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $32 $132 $37–$438 $132
2022 $836 $155 $48–$522 $149
2023 $1,198 $167 $52–$557 $160
2024 $1,762 $178 $55–$600 $164
2025 $1,631 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,112 53 payments
  2. Janssen Biotech, Inc. $801 24 payments
  3. Sun Pharmaceutical Industries Inc. $752 41 payments
  4. UCB, Inc. $497 19 payments
  5. Amgen Inc. $395 16 payments
  6. Novartis Pharmaceuticals Corporation $376 19 payments
  7. Incyte Corporation $363 12 payments
  8. E.R. Squibb & Sons, L.L.C. $301 22 payments
  9. Lilly USA, LLC $237 13 payments
  10. Genzyme Corporation $183 8 payments
  11. Other $441 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,796 238 payments
  2. Education $663 7 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $888 24 payments
  2. SKYRIZI $717 34 payments
  3. Bimzelx $430 16 payments
  4. ILUMYA $404 34 payments
  5. Otezla $395 16 payments
  6. OPZELURA $363 12 payments
  7. SOTYKTU $301 22 payments
  8. DUPIXENT $275 12 payments
  9. COSENTYX $271 14 payments
  10. RINVOQ $259 14 payments
  11. Other $1,387 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,224

Median for Physician Assistant: 241

Drug cost

$208,513

Median for Physician Assistant: $4,110

Branded share of claims

5.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 13 $137,089
Dupixent Pen Dupilumab Brand 11 $40,780
Ketoconazole Generic 277 $5,770
Clobetasol Propionate Generic 81 $3,576
Clindamycin Phosphate Generic 60 $2,975
Triamcinolone Acetonide Generic 194 $2,685
Fluorouracil Generic 36 $2,170
Tacrolimus Generic 14 $1,778
Metronidazole Generic 25 $1,443
Ammonium Lactate Generic 55 $1,354

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$237,334

Of which drugs: $79

Medicare patients

1,296

Average age 76

Services billed

7,699

411 women, 885 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 43%
Chronic kidney disease 27%
Diabetes 26%
Ischemic heart disease 23%
Atrial fibrillation 18%
Cancer 16%
Depression 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Methotrexate sodium, 50 mg J9260 Office 16 27 $57
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 30 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $347
$347 — —
SKYRIZI
  • AbbVie, Inc. $266
$266 — —
Otezla
  • Amgen Inc. $213
$213 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $164
$164 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $151
$151 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

245 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record